SCHEMBL4718588

SCHEMBL4718588

CNc1ccc([N+](=O)[O-])nc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
ALDH1A1 P00352 5/20 0.45
HCAR3 P49019 1/20 0.38
HTT P42858 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 3/20 0.36
POLB P06746 2/20 0.36
GALR2 O43603 1/20 0.36
CDC25B P30305 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
TLR2 O60603 1/20 0.33
TLR1 Q15399 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
OPRD1 P41143 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12588533 0.76 ALDH1A1 (0.42) MAPTALDH1A1KDM4EGAARECQL
SCHEMBL4715632 0.74 MAPT (0.53) MAPTALDH1A1KDM4EGAARECQL
SCHEMBL1002218 0.72 ERN1 (0.38) MAPTALDH1A1HTTKDM4EGAA
SCHEMBL2031745 0.71 MEN1 (0.46) MAPTALDH1A1HTTKDM4EGAA
SCHEMBL6907376 0.70 MAPK1 (0.38) MAPTALDH1A1KDM4EGAALMNA
SCHEMBL18878176 0.69 CCR1 (0.37) MAPTALDH1A1HSD17B10RAB9ACYP1A2
SCHEMBL2488382 0.68 ALDH1A1 (0.41) MAPTALDH1A1HTTKDM4EGAA
SCHEMBL27711672 0.68 HSP90AB1 (0.38) MAPTALDH1A1HTTKDM4EGAA
SCHEMBL4161984 0.68 ALDH1A1 (0.40) MAPTALDH1A1LMNANPC1RAB9A
SCHEMBL15595531 0.67 LRRK2 (0.32) ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490367-B1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-07-23 EP disclosed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 US disclosed
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors NR4A3, XDH, MAPK8 MAPT 4618/4885ALDH1A1 4524/4885HCAR3 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.